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The pathologic growth of new blood vessels is the common ﬁnal
pathway in proliferative diabetic retinopathy (PDR), and often leads
to a catastrophic loss of vision due to vitreous hemorrhage and/or
tractional retinal detachment. In diabetic retinopathy, hypoxia ap-
pears to be the primary stimulus to neovascularization by upregu-
lating the production of angiogenic stimulators, and by reducing
the production of angiogenic inhibitors, there by disturbing the bal-
ance between the positive and negative regulators of angiogenesis.
Vascular endothelial growth factor (VEGF) and its cognate receptors
are critical mediators of angiogenesis, mediating endothelial cell
proliferation, migration, and tube formation [1]. Recently, pigment
epithelium-derived factor (PEDF) has been shown to be a highly
effective inhibitor of angiogenesis as it speciﬁcally inhibits the
migration of endothelial cells. It was also shown that PEDF contrib-
utes to most of the antiangiogenic activity in the vitreous [2]. The
elevated intraocular levels of the angiogenic VEGF [3,4] and de-
creased intraocular levels of the antiangiogenic PEDF [5] in patients
with PDR have previously been demonstrated. The data support the
concept that induction of angiogenesis in PDR requires not only ele-
vation of angiogenic growth factors such as VEGF but also a de-
crease in angiogenesis inhibitors such as PEDF. In addition, strong
evidence indicates that chronic, low-grade subclinical inﬂamma-
tion is implicated in the pathogenesis of diabetic retinopathy [6].
All the hypoxia-dependent events in cells appear to share a
common denominator: the hypoxia-inducible factor (HIF)-1, which
is a heterodimeric transcription factor. HIF-1 is composed of HIF-
1a and HIF-1ß subunits, which are both members of the basic he-
lix-loop-helix-PAS family of proteins. Whereas, the ß-subunit pro-
tein is constitutively expressed, the stability of the a-subunit and
its transcriptional activity are precisely controlled by the intracel-
lular oxygen concentration. Under normoxia, the level of HIF-1a
protein is kept low through rapid ubiquitylation, and subsequent
proteasomal degradation. In cells under hypoxia, the ubiquityla-
tion and subsequent degradation of HIF-1a protein is suppressed,
resulting in accumulation of the protein to form an active complex
with HIF-1ß [7–9]. Under hypoxic conditions, HIF-1 triggers the
activation of a large number of genes encoding proteins that regu-
late angiogenesis, such as VEGF, erythropoietin (EPO) and angio-
poietins (Angs) [10–13]. Because hypoxia, a central pathogenic
stimulus in PDR, induces HIF-1a that can induce the angiogenic
molecules VEGF, Epo and Angs, we investigated the expression
and distribution of these proteins in PDR ﬁbrovascular epiretinal
membranes. In addition, we studied the expression of the angio-
genic inhibitor PEDF and the correlation between the number of
leukocytes and the expression of angiogenic factors in PDR epireti-
nal membranes. The levels of vascularization and proliferative
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In this immunohistochemical study of PDR epiretinal ﬁbrovas-
cular membranes, there were four important ﬁndings [14]: The
ﬁrst ﬁnding with PDR membranes showed immunoreactivity for
the transcriptional regulator HIF-1a (Fig. 1A) and its target angio-
genic factors Ang-2 (Fig. 1B) and VEGF (Fig. 1C) on vascular endo-
thelial, whereas there was no immunoreactivity for Epo, Ang-1,
and PEDF. The second ﬁnding was signiﬁcant correlations between
the number of blood vessels expressing the panendothelial marker
CD34 and the number of cells expressing the proliferating cell
markerKi-67 and the number of blood vessels expressing Ang-2
and VEGF. Third, the number of blood vessels expressing Ang-2
and VEGF in membranes from patients with active PDR were sig-
niﬁcantly higher than that in the membranes from patients with
inactive PDR, and the number of blood vessels expressing Ang-2
and VEGF correlated signiﬁcantly. Fourth, signiﬁcant correlations
between the number of leukocytes expressing the leukocyte com-
mon antigen CD45 and the number of blood vessels expressing
Ang-2 and VEGF. Taken together, our ﬁndings suggest that selec-
tive expression of HIF-1a, Ang-2 and VEGF, but not Ang-1 and
PEDF, in diabetic epiretinal membranes may favour aberrant neo-
vascularization and endothelial abnormalities.
HIF-1amediates the angiogenic response to hypoxia by upregu-
lating the expression of multiple angiogenic factors [10–13]. In a
rabbit model of hind limb ischemia, administration of DNA plasmid
encoding HIF-1a/VP16 increased angiogenesis and blood supply
[15]. Recently, Matsuda et al. [16] demonstrated that HIF-1a DNA
induced angiogenesis in a rat cerebral ischemiamodel. Overexpres-
sion of HIF-1a in tumor tissues has been correlated with increased
tumor angiogenesis, aggressive tumor growth, and poor patient
prognosis [17–20]. In the present study, we demonstrated that
HIF-1a was speciﬁcally localized in vascular endothelial cells in
PDR ﬁbrovascular epiretinal membranes. Our observations are con-
sistent with previous reports showing that exposure to hypoxia in-
duced a signiﬁcant increase of HIF-1a protein expression in vascular
endothelial cells in vitro [21,22], and in vivo [23]. In vitro studies
demonstrated that direct infection of vascular endothelial cellswith
Ad2/ HIF-1a/VP16 promoted endothelial cell proliferation and tube
formation that was attributable to increasedmRNA and protein lev-
els of VEGF and Ang-2, but not Ang-1. It was also demonstrated that
HIF-1mediated the hypoxic upregulation of VEGF, andAng-2 in vas-
cular endothelial cells [13]. These ﬁndings suggest that HIF-1a is in-
volved in angiogenesis in PDR epiretinal ﬁbrovascular membranes.
Further support that HIF-1a is associated with diabetes comes from
Chavez et al. [24], who showed that the expression of HIF-1a and its
target genes are increased in the nerves of diabetic rats.
In conclusion, the present data suggest production of HIF-1a and
its target angiogenic factors VEGF andAng-2 by vascular endothelial
cells in diabetic ﬁbrovascular epiretinal membranes and local auto-
crine action of these proteins in stimulating angiogenesis. Clinically,pen access under CC BY-NC-ND license.
Fig. 1. Proliferative diabetic retinopathy epiretinal membranes. (A) Immunohisto-
chemical staining for hypoxia-inducible factor-1a showing immunoreactivity on
vascular endothelial cells (original magniﬁcation 100). (B) Immunohistochemical
staining for angiopoietin-2 showing immunoreactivity on vascular endothelial cells
(original magniﬁcation 100). (C) Immunohistochemical staining for vascular
endothelial growth factor showing immunoreactivity on vascular endothelial cells
(original magniﬁcation 100).
56 Special Commentary / International Journal of Diabetes Mellitus 1 (2009) 55–56manipulating the HIF-1a pathway in the treatment of diabetic reti-
nopathy might be an attractive choice in comparison to targeting
VEGF and other growth factor that localize downstream. It has been
demonstrated that the HIF-1a pathway can be used as a therapeutic
target for development of novel cancer therapeutics [25].
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